securities 1,150,516 --
Deferred compensation expense 28,750 --
Change in operating assets and
liabilities
Accounts receivable (7,246,740) (3,308,650)
Accounts receivable - related
parties (1,403,383) (245,420)
Notes receivables 59,790 (29,473)
Inventories 27,542 1,065,113
Other receivables (254,886) (937)
Other receivables - related
parties (81,384)
Advances to suppliers (488,064) (10,316)
Other assets 96,538 1,282,175
Accounts payable 1,159,105 (2,324,940)
Accrued liabilities 301,290 58,191
Other payables 2,146,659 (1,355,440)
Other payables - related parties (962,509) (592,232)
Liabilities from discontinued
operations (1,162,133) --
Taxes payable 10,006,057 2,011,128
Net cash provided by operating
activities 17,697,452 4,283,404
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of marketable
securities 605,882 --
Payment for land use right (8,246,830) --
Purchase of equipment (401,302) (58,469)
Cash receipt from reverse
acquisition 534,
'/>"/>
| SOURCE Genesis Pharmaceuticals Enterprises, Inc. Copyright©2008 PR Newswire. All rights reserved |